CPRX — Catalyst Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $3.85bn
- $3.10bn
- $588.99m
Catalyst jumps after Q4 revenue beat
Brief: Catalyst Pharmaceuticals Q4 Revenue USD 110.6 Million Vs. IBES Estimate USD 105.9 Million
Catalyst Pharmaceuticals Inc expected to post earnings of 27 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Greenbrier, Abercrombie & Fitch
U.S. STOCKS ON THE MOVE-CVS Health, Peloton, Eli Lilly
U.S. STOCKS ON THE MOVE-Conagra Brands, Voyager Therapeutics, McDonald's
Brief: Catalyst Pharmaceuticals, Inc. Announces Pricing Of Public Offering Of Common Stock
Catalyst Pharma falls on pricing $150 mln stock deal
Brief: Catalyst Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Brief: Catalyst Pharmaceuticals Says FIRDAPSE New Drug Application Submitted in Japan by Partner DyDo Pharma
Brief: Catalyst Pharmaceuticals Says CFO Alicia Grande To Retire At End Of 2023
Brief: Catalyst Pharmaceuticals Q3 Revenue USD 102.7 Million Vs. IBES Estimate USD 100.4 Million
U.S. RESEARCH ROUNDUP-Caterpillar, Intel, Yelp
Brief: Santhera Pharmaceuticals: FDA Approved AgamreeFor Treatment Of Duchenne Muscular Dystrophy
US FDA approves Santhera's drug for rare muscular dystrophy (updated)
U.S. STOCKS ON THE MOVE-American Airlines, Netflix, Tesla
Catalyst Pharmaceuticals names new CEO, shares down
Brief: Catalyst Pharmaceuticals Appoints Richard J. Daly as CEO
Brief: Catalyst Pharmaceuticals Announces FDA Acceptance Of The Supplemental New Drug Application For FIRDAPSE®